|
But sometimes the biggest breakthroughs are. In this episode of Med Tech Gurus, Professor Mark Kendall—former rocket scientist turned MedTech innovator—shares a vision that could reshape how we monitor health. A sticker-like wearable that captures real bio signals from the body—without needles, without bulky devices A Shift in How We Think About Wearables Today’s wearables sit on the surface. More advanced devices require invasive approaches. This technology bridges that gap—delivering meaningful data in a way that is simple, scalable, and patient-friendly. It’s not just an incremental improvement. It’s a rethink of how we access the body. Why Start with Hydration? The first application is hydration. At first glance, that may not seem groundbreaking. But hydration is a massive, under-recognized health issue—impacting everything from athletic performance to surgical outcomes and long-term health. And today, we still lack reliable, real-time ways to measure it. More Than a Device......What makes this innovation compelling is not just the form factor. It’s what comes next. This platform has the potential to expand into monitoring for:
The bigger take away, the future of MedTech won’t just be about better data. It will be about:
Listen to the Full Episode Episode #333: Stickers That Can Save Lives Or Watch on Youtube Please remember to like and subscribe!
0 Comments
The Problem No One Talks AboutMost MedTech startups don’t fail because the science is wrong.
They fail because no one changes behavior. That was the core takeaway from our conversation with Noël Theodosiou, CEO of Luminous—who is helping life sciences companies confront a growing gap between innovation and real-world adoption. The Industry Playbook (And Why It Falls Short)The traditional path looks like this:
In reality, many products stall after launch. Why? Because this model assumes clinical success leads to adoption. It doesn’t. Built for the Lab. Sold Into Reality.Clinical environments are controlled. Healthcare delivery is not. Patients don’t behave like trial participants. Providers don’t operate like your pitch deck. Health systems don’t move on your timeline. And most importantly: Up to 80% of health outcomes are driven outside of clinical care The Risk Most Teams Miss: AdoptionCompanies spend significant time de-risking:
Adoption This includes:
What We’re Seeing Right NowGLP-1s: Breakthrough Meets RealityStrong clinical outcomes—but real-world usage is driven by:
AI Is Changing the Entry PointPatients are no longer starting with providers. They’re starting with:
“Patient-Centric” Isn’t Operational YetThe industry talks about patient centricity. But rarely builds with patients during development. The Shift: Innovation → AdoptionThe next wave of successful companies will:
The Reality for Founders & InvestorsIf your product requires:
You have a go-to-market risk disguised as innovation. Final ThoughtThe market does not reward innovation alone. It rewards adoption. The companies that understand this will lead. The ones that don’t will struggle to scale. Listen to the Full Episode🎧 Episode #331: The Patient Trust Shift Stroke remains one of the leading causes of death and long-term disability worldwide. Yet the tools and techniques used to treat stroke have advanced dramatically over the past decade. In this episode of Med Tech Gurus, we speak with Adam Arthur, Chief Medical Officer for Neurovascular at Medtronic, about how medical technology is expanding the reach of life-saving stroke care.
Dr. Arthur brings more than two decades of experience as a neurosurgeon, clinical researcher, and educator. His transition from the operating room to industry leadership was driven by a powerful idea: the opportunity to help more patients by scaling clinical innovation through medical technology. From Clinical Insight to Global Innovation throughout his career, Dr. Arthur has participated in major clinical trials and contributed to advances in neurovascular treatment. One of the most important lessons he has learned is that generating meaningful clinical evidence is both complex and essential. Every study requires careful design, collaboration across institutions, and deep attention to detail in order to answer the right clinical questions. But when those efforts succeed, the results can reshape patient care. Technologies such as thrombectomy, carotid stenting, and flow diversion have dramatically improved outcomes for patients suffering from stroke and related neurovascular conditions. Expanding the Reach of Neurovascular Therapies one of the most exciting trends in neurovascular innovation is the ability to apply existing technologies to new clinical challenges. Dr. Arthur highlighted how treatments like Onyx—an embolization therapy used for decades—are now being studied for conditions such as chronic subdural hematoma, potentially opening new treatment pathways for patients. This kind of innovation often comes from a combination of clinical insight and technological refinement. By better understanding disease mechanisms and improving device design, physicians and engineers can extend the impact of therapies far beyond their original applications. The Next Frontier in Stroke Care looking ahead, the future of stroke care may involve even more advanced technologies. Emerging innovations such as artificial intelligence, robotics, and enhanced imaging could make neurovascular interventions faster, more precise, and more widely accessible. For example, improvements in thrombectomy techniques are already reducing the time required to restore blood flow to the brain. In the longer term, robotic systems may enable remote procedures, bringing advanced stroke treatment to hospitals and regions that currently lack specialized expertise. Lessons for MedTech Innovators Dr. Arthur also shared valuable insights for entrepreneurs and innovators working in medical technology. One of the most important lessons is the value of collaboration between physicians and industry partners. Clinicians provide essential real-world insights into patient care, while engineers and developers translate those insights into practical solutions. Equally important is the willingness to learn quickly and adapt. Not every idea will succeed, but rapid feedback and honest evaluation can help innovators pivot toward better solutions. In the complex world of healthcare innovation, failing fast and learning quickly can ultimately lead to better patient outcomes. The Power of Scaling Care perhaps the most compelling takeaway from this conversation is the power of medical technology to scale clinical expertise. A single surgeon can help hundreds or thousands of patients during a career. But when that surgeon’s insights inform a new device or therapy, the impact can reach millions. For Dr. Arthur and his team, that is the true promise of neurovascular innovation: developing technologies that extend life-saving care to more patients, in more places, and with better outcomes. For anyone interested in MedTech innovation, stroke treatment, neurovascular devices, clinical research, and physician-industry collaboration, this episode offers a powerful look at how clinical insight and technology come together to shape the future of medicine. Listen to the full episode on Med Tech Gurus to hear Dr. Arthur’s perspectives on innovation, collaboration, and the evolving landscape of stroke care.
How Two Surgeons Built the "LinkedIn for Surgeons" — And Why It’s Changing the Game In an era where digital health platforms are transforming every corner of medicine, two surgeons--Dr. Jeremy Heffner and Dr. Mark Soliman—are leading a revolution in surgical education and collaboration.
Together, they co-founded Surgeon—a secure, surgeon-only platform that blends the best of LinkedIn, YouTube, and real-time surgical consulting into one purpose-built space for global collaboration. Their goal? To democratize surgical knowledge, connect brilliant minds, and improve patient care worldwide. Why Surgeon MattersDr. Heffner and Dr. Soliman realized a core problem: surgical knowledge was locked behind academic silos, inaccessible conferences, or outdated social media. So they built Surgeon as a digital hub where surgeons can:
Tech That Solves Real ProblemsSurgeon isn’t just another app—it’s tailored to the realities of modern surgical life. Case in point: SurgeonScribe, their HIPAA-compliant AI transcription tool that lets surgeons focus on patients, not paperwork. It captures notes in real time, freeing clinicians from their EMR grind. They’ve also built functionality for:
Scaling With PurposeBootstrapped and fueled by passion, Surgeon has become a case study in purpose-driven MedTech entrepreneurship. By fostering cross-industry collaboration—with surgeons, engineers, and device manufacturers alike—they’re unlocking innovation and elevating care. Their ultimate vision? To become the Amazon of surgical collaboration—a single, unified ecosystem where education, networking, and innovation converge for the benefit of every patient. Listen to the full conversation on Med Tech Gurus Episode #282 YouTube Episode #282 Tackling Antibiotic Resistance: How AI Is Revolutionizing Drug DiscoveryAntibiotic resistance is one of the most pressing global health challenges of our time. Each year, millions of people face infections that no longer respond to conventional treatments. But what if artificial intelligence (AI) could hold the key to developing the next generation of life-saving drugs?
In a recent episode of Med Tech Gurus, we spoke with Alan D. Roth, Chief Executive of Oxford Drug Design, about how his team is harnessing AI to transform drug discovery and development. With their innovative Synth AI platform, Oxford Drug Design is addressing not only antibiotic resistance but also advancing treatments for cancer and other critical diseases. The Power of AI in Drug DiscoveryTraditional drug development is notoriously slow and expensive, often taking over a decade and billions of dollars to bring a new therapy to market. Oxford Drug Design is rewriting this playbook by leveraging AI and computational chemistry to:
Building Innovation in Life SciencesAlan also shared insights into what it takes to innovate in the highly regulated world of healthcare technology. From balancing scientific focus with creative exploration to navigating the complexities of raising capital, Oxford Drug Design’s journey offers invaluable lessons for entrepreneurs and healthcare leaders alike. Why This MattersWith antibiotic resistance on the rise and new diseases emerging, the need for faster, smarter drug discovery has never been greater. AI platforms like Synth AI are bridging the gap between cutting-edge science and patient-ready solutions—opening doors to a healthier future. Want the full story? Listen to the episode now and hear how Alan Roth and his team are transforming healthcare with artificial intelligence. Listen to Episode #267: Tackling Antibiotic Resistance and Beyond Want to watch the episode on Youtube? https://www.youtube.com/watch?v=fDMOqCvmSt8 In the rapidly evolving landscape of medtech startups, safeguarding intellectual property (IP) is paramount. Stan Gibson, a seasoned legal expert with over 30 years of experience, sheds light on the crucial steps startups should take to protect their innovations and navigate the complex commercialization process. The Importance of Contract Manufacturing For many medtech startups, contract manufacturing, whether onshore or offshore, is an integral part of their business model. Gibson emphasizes the necessity of involving legal experts early in the process to avoid potential pitfalls. He recounts a client's experience with a poorly drafted contract that led to litigation: "This contract was just bad enough to get me sued and just good enough to win," he says. Such situations are best avoided, as litigation is both time-consuming and costly. To prevent these issues, Gibson advises that startups ensure non-disclosure agreements (NDAs) and assignments are in place from the outset. This is crucial for protecting any intellectual property developed by the contract manufacturer, ensuring that ownership remains with the company funding the work. Early legal involvement can prevent costly disputes and save significant resources in the long run. The Value of Early Legal Involvement Gibson stresses the importance of engaging legal professionals early in the product development process. "Bringing in lawyers at the beginning is much less expensive than litigating a dispute later, which can cost hundreds of thousands of dollars," he notes. This proactive approach allows startups to navigate the complexities of patent law and develop a robust IP portfolio. Having patent attorneys involved in product development discussions helps entrepreneurs understand which aspects of their innovation should be patented. This collaboration creates a strong IP portfolio that can deter competitors and protect the company's market position. A well-developed patent portfolio, often referred to as a "patent thicket," can be a significant asset, making it harder for competitors to infringe on the company's IP. Building a Strong Patent Portfolio A comprehensive patent strategy is essential for medtech startups. Patents begin with a specification and claims that define the boundaries of the patent. Gibson explains that additional claims can be added in subsequent patents, creating a robust "patent thicket." This strategy not only protects the innovation but also enhances the company's value during acquisitions or public offerings. Potential buyers or investors look for strong IP portfolios as they indicate the company's ability to safeguard its innovations against competitors. Proper documentation and clear ownership of patents are critical during due diligence processes for funding or acquisition. "You want to make sure you have proper assignments from the beginning," Gibson advises, as this prevents disputes over ownership that can derail the commercialization process. The Importance of Documentation and Assignments Ensuring clear ownership of patents through proper documentation and assignments is crucial. This becomes particularly important during due diligence processes for funding or acquisition. Properly documented IP rights facilitate smoother funding rounds and enhance the company's attractiveness to potential investors or acquirers. "You want to make sure you have proper assignments from the beginning. This prevents disputes over ownership that can derail the commercialization process," Gibson emphasizes. Innovations in the Courtroom Gibson's innovative approach extends to the courtroom, where he has used detailed animations to explain complex medical procedures. He recalls a case involving spinal fusion surgeries where animations helped the jury understand the technology without being overwhelmed by graphic surgical footage. "We wanted ways to bring the surgery into the courtroom without the blood and gore. Animations showed the implants and methods clearly, helping the jury understand the technology," he explains. This innovative use of technology in the courtroom underscores the importance of clarity and precision in legal proceedings involving complex medical technologies. The Path to Commercialization Navigating the commercialization process can be challenging for medtech startups. Gibson advises that having a well-protected IP portfolio is key to attracting funding and avoiding disputes. "One of the biggest impediments to commercialization is funding. Ensuring your IP is protected can help secure funding and prevent boardroom squabbles that delay progress," he says. Periodic IP health checks are also recommended to ensure the portfolio remains robust and up-to-date. This proactive approach can help startups identify potential issues early and address them before they become significant problems. Looking Ahead Gibson's goal is to help 10,000 entrepreneurs and inventors at an early stage, preventing the need for costly litigation. By educating startups through resources like the IP Checklist, he aims to help them protect their innovations from the outset. For more information about Stan Gibson and his IP Checklist, visit www.ip-checklist.com. Med Tech Gurus Episode #242
Reimagining Cleanliness: A Revolution in Disinfection with Viking Pure Solutions Daniel Lawson was recently a guest on Med Tech Gurus Episode #242. Daniel brought some great insights regarding disinfection agents. The disinfection and cleaning industry is undergoing a revolutionary transformation, thanks to Viking Pure Solutions. Co-founded by Daniel Lawson, Viking Pure is dedicated to reimagining how we clean and disinfect by introducing an environmentally conscious, patent-protected technology that is set to change the game. A Journey from Neurospine to Disinfection Daniel Lawson, co-founder and president of business affairs at Viking Pure, spent nearly twelve years in the spine implant technology sector before transitioning to infection prevention. His experience in maintaining sterile conditions and witnessing the devastation caused by infections inspired him to research electrolized water and its applications. This research became the foundation of Viking Pure Solutions. The Leap to Entrepreneurship Starting Viking Pure wasn't an easy decision. Initially a side project, Viking Pure required evenings and weekends of dedication. The real challenge was deciding when to leave secure jobs and commit fully to the venture. Customer feedback and significant moments of success validated their efforts, making the leap into entrepreneurship a calculated risk worth taking. Best Practices for Commercializing Innovation Introducing disruptive technology in the healthcare industry requires more than just innovation. It demands a deep understanding of the industry and a commitment to education. Viking Pure offers customers the opportunity to try their technology at no cost, accompanied by ongoing education and certification. This approach ensures customers understand and trust the benefits of the technology, facilitating adoption and driving change. Addressing COVID-19 and ESG Concerns The COVID-19 pandemic heightened awareness of infection risks and emphasized the importance of Environmental, Social, and Governance (ESG) initiatives. Viking Pure Solutions addresses these concerns by building electrolysis water generators that produce hospital-grade disinfectant and multipurpose cleaning solutions using only water, salt, and electricity. These solutions are non-toxic and safe for the environment, effectively meeting regulatory requirements without the risks associated with traditional chemicals. Reducing Waste and Ensuring Safety One of the significant issues in healthcare is the disposal of chemical residues. Viking Pure Solutions tackles this by generating chemicals on-site, eliminating the need for single-use disposables. This not only reduces waste but also offers substantial cost savings. For example, a hospital system working with Viking Pure saves approximately $40,000 annually on recycling costs by producing its chemicals on-site. Redefining Cleanliness The traditional belief that cleanliness is associated with the smell of bleach or citrus is a misconception propagated by the chemical industry. True cleanliness, as advocated by Viking Pure, has no smell. Viking Pure’s solutions are effective without added fragrances, making them safer for both users and the environment. The Future of Disinfection Daniel Lawson and Viking Pure Solutions are at the forefront of a revolution in the cleaning and disinfection industry. Their innovative, environmentally friendly technology sets a new standard for what it means to be truly clean. By focusing on education, safety, and sustainability, Viking Pure is not only transforming cleaning practices but also contributing to a healthier planet. In conclusion, Viking Pure Solutions is pioneering a new era in disinfection and cleaning. Their commitment to eliminating toxic chemicals and reducing environmental impact is a significant step forward for the industry. Daniel Lawson's journey from neurospine technology to infection prevention exemplifies the innovative spirit needed to drive meaningful change. As the world becomes more conscious of the importance of safe and sustainable cleaning practices, Viking Pure Solutions is poised to lead the way.  We're thrilled to feature Amanda Proscia, co-founder of Lightspeed Public Relations and Marketing, on the latest episode of Med Tech Gurus! 🎙️
In Episode 241, titled "Getting Market Buzz," Amanda dives deep into the dynamic world of health tech PR. She shares invaluable insights on building strong reputations, showcasing groundbreaking innovations, and overcoming commercialization challenges. Whether you're a startup or a seasoned professional, Amanda's expertise provides actionable strategies to elevate your brand and succeed in the competitive med tech landscape. This episode is packed with tips and strategies essential for anyone looking to make a significant impact in the med tech industry. Don't miss out on learning from one of the best in the business. Tune in now to get the buzz on market buzz! 📈 #MedTech #PublicRelations #HealthcareInnovation #Podcast |
